Aurobindo Pharma

US And European Pressures Will Drive Margin Compression

AnalystLowTarget

Not Invested

Community Contributor

Published

21 Jun 25

AnalystLowTarget's Fair Value

₹862.80

30.4% overvalued

10 Sep

₹1,124.80

-24.0%

3.2%

-24.0%

3.2%

You can edit this narrative until Jun 21 10:11 PM. Then, changes will post as Updates.

Author's Valuation

₹862.830.4% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

₹862.8

30.4% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.83%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.73%

Calculation

₹45.19b

Earnings '28

15.62x

PE Ratio '28

₹705.74b

Market Cap '28

₹705.74b

Market Cap '28

571.80m

No. shares '28

₹1.23k

Share Price '28

₹1.23k Share Price '28

Discounted to 2025 @ 12.73% p.a.

₹861.59

Fair Value '25